Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib + Quercetin in Idiopathic Pulmonary Fibrosis
NCT02874989Phase 1Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in idiopathic pulmonary fibrosis (IPF) comparing Dasatinib + Quercetin with Placebo (2 arms). Primary endpoints: Percentage of pro-inflammatory expressing cells at 4 weeks, Blood Pressure at 4 weeks and 11 more. Started Dec 2016; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02874989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02874989.